MorphoSys Completes Sale of AbD Serotec to Bio-Rad

2013-01-10 15:33:31 -
MorphoSys AG /
MorphoSys Completes Sale of AbD Serotec to Bio-Rad
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
sale  of its  research and  diagnostic antibody  segment AbD  Serotec to Bio-Rad
Laboratories,  Inc.  (NYSE:  BIO  and  BIOb)  has been completed. All assets and
liabilities  of the AbD Serotec segment of MorphoSys AG as well as all shares of
the  subsidiaries MorphoSys UK  Ltd., MorphoSys AbD  GmbH and MorphoSys US, Inc.
have been transferred to Bio-Rad.

"We  are delighted  to have  reached the  closing of  the transaction 
  
    
      
        

	    
  
  just a few
weeks  after  the  announcement  was  made.  With  the divestment of AbD Serotec
completed,  MorphoSys can devote 100% of its  attention to building value in its
core therapeutics business," commented Jens Holstein, Chief Financial Officer of
MorphoSys AG.



About MorphoSys:
MorphoSys  developed HuCAL, the  most successful antibody  library technology in
the  pharmaceutical industry. By  successfully applying this  and other patented
technologies,  MorphoSys  has  become  a  leader  in  the  field  of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together  with its  pharmaceutical partners,  MorphoSys has  built a therapeutic
pipeline  of more  than 70 human  antibody drug  candidates for the treatment of
cancer,  rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its  ongoing  commitment  to  new  antibody  technology  and  drug  development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit  www.morphosys.com

HuCAL(®),  HuCAL GOLD(®), HuCAL  PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®)
and  Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®)  is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a
subsidiary of MorphoSys AG.


This  communication contains  certain forward-looking  statements concerning the
MorphoSys  group of  companies. The  forward-looking statements contained herein
represent  the judgment of MorphoSys as of  the date of this release and involve
risks  and  uncertainties.  Should  actual  conditions differ from the Company's
assumptions,  actual  results  and  actions  may  differ from those anticipated.
MorphoSys  does not intend to update  any of these forward-looking statements as
far as the wording of the relevant press release is concerned.



For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com 

Media Release (PDF): 
 hugin.info/130295/R/1669504/542406.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1669504]